Institute of Cancer

7/31/2019 Institute of Cancer

1/30

POSTGRADUATEPROSPECTUSTHE INST ITU TE O F C ANC ER R ESEAR CH, LO NDON


2/30

ContentsWelcome rom Academic Dean - Proessor Alan Horwich 3

Vision and Mission 4

10 Reasons to Choose the ICR 5

Meet the Student President 8

Meet our Alumni 9

ICR Research Sections:

Chelsea Site

The Breakthrough Toby Robins Breast Cancer Research Centre 11

Gene Function and Regulation 12

Structural Biology 12Cell and Molecular Biology (including the Cancer Research UK Tumour Cell Signalling Unit) 13

Sutton Site

Cancer Therapeutics (including the Cancer Research UK Cancer Therapeutics Unit) 14

Cancer Research UK/EPSRC Imaging Centre 15

Epidemiology 15

Joint Department o Physics 16

Academic Radiotherapy and Department o Radiotherapy (including the Psychology Research Group) 17

Clinical Trials 17

Cancer Genetics 18

Paediatric Oncology 18

Haemato-oncology 19

Medicine 20

Molecular Carcinogenesis 21

Our Campus 22

Student Support and Resources 23

e-Learning Resources 24

Library and Inormation Services 25

The Registry 26

Learning and Development 26

Our Commitment to Equality and Diversity 28

Condentiality and Data Protection 28

How to Apply 29

Senior Ocers and Academic Deans Team 30


3/30

Welcome rom Academic DeanThe Institute o Cancer Research is at the oreront o science in the ght

against cancer and we are proud o our international reputation. This

prospectus is designed to give you a avour o lie here by introducing our

wide variety o research activities and it advises on the next steps i you want to

develop your career with us in this dynamic environment.

Cancer research itsel in all its many aspects ofers unparalleled challenges,

intellectually and practically, in a very wide range o subjects, including physics

and chemistry as well as cell and molecular biology. The ICR is ortunate in

its close partnership withThe Royal Marsden NHS Foundation Trust, which

acilitates translational research.

Our Scientic Strategy is based around exploiting knowledge o cancer genes or patient benet, achieved

through development o therapeutic technologies, discovery o better tools or diagnosis and clinicalmonitoring, and analysis o how genetic background may predispose to cancer and inuence response to

therapy.

The ICR has made many important contributions to cancer research through its ocus on a combination

o genetics, molecular biology, drug discovery and development, and cancer diagnosis and treatment.

The quality o our research was armed by the Higher Education Funding Councils Research Assessment

Exercise in 2008. The Times Higher Education analysis o these results ranked us rst amongst all UK

universities entering more than one subject area o assessment, with 37% o our research scoring 4 star

(world-leading) and a urther 42% scoring 3 star (internationally excellent).

As well as high standards o research, we seek to provide high quality training or all our graduate students.We have a programme o academic activities designed to complement the day-to-day research laboratory

experience o science. We want your time with us to be ruitul, productive and enjoyable and we aim to

equip you with a range o outstanding skills as a springboard or your uture career. We are proud that

our graduateshave gone on to make signicant discoveries in the eld o cancer research and treatment,

thereby improving and enriching the lives o many people.

Thank you or the interest you have shown in our work and good luck in your research career.

Proessor Alan Horwich

POSTGRADUATE PROSPECTUS PAGE 3
http://www.royalmarsden.nhs.uk/homehttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/about_us/scientific_strategy/index.shtmlhttp://www.icr.ac.uk/education/clinical_trainee_opportunities/meet_alumni/index.shtmlhttp://www.icr.ac.uk/education/clinical_trainee_opportunities/meet_alumni/index.shtmlhttp://www.icr.ac.uk/education/clinical_trainee_opportunities/meet_alumni/index.shtmlhttp://www.icr.ac.uk/about_us/scientific_strategy/index.shtmlhttp://www.royalmarsden.nhs.uk/home


4/30

Vision and Mission

Our VisionIs that people may live their lives ree rom the ear o cancer as a lie threatening disease

Our MissionIs to relieve human sufering by pursuing excellence in the ght against cancer through:

Research into the causes, prevention, diagnosis and methods of treatment of cancer

Education and advanced training of medical and scientic sta

Treatment and care of the highest quality for cancer patients

Attraction and development of resources to the optimum eect



5/30

10 Reasons to Choose the ICR

1 Excellent Financial SupportPhD studentships unded by the ICR, Cancer Research UK, MRC or EPSRC are supported or our years.

The 2011/12 non-taxable stipend will be 19,500 (inner London - Chelsea) or 18,180 (outer

London Sutton). A number o Wellcome Trust studentships with higher stipends are also available.

2 University o London Degree and BenetsWe are a College o the University o Londonand as such our students graduate rom a globally

recognised world leader in higher education. All our students have ull access toThe University o

London Union (ULU)sports clubs, societies and acilities including gym, swimming pool, caes, bars

and music venues.

3 Support rom World-ClassResearchersAll our students receive advanced scientic

training at the cutting edge o cancer research

guided by a aculty o world-class researchers.

To date, all o our PhD submissions have been

successul. In 2007 we were third highest in the

Higher Education Funding Council or Englands

report on Research Degree Qualication Rates,

and our qualication rates remain high.

4 Proven Scientic ExcellenceOur record o achievement in understanding

the genetic epidemiology and molecular

pathology o cancer and our work in the area o

therapeutic development is second-to-none.

We are the most efective University in

the UK in terms o the impact on our scientic

peers o our published work in biomedical

sciences (Source: Evidence Ltd). The qualityo our research was armed by the Times Higher

Educations interpretation o the 2008 Research

Assessment Exercise, which ranked the ICR as

the UKs top academic research centre.

http://www.lon.ac.uk/http://www.ulu.co.uk/http://www.ulu.co.uk/http://www.ulu.co.uk/http://www.ulu.co.uk/http://www.lon.ac.uk/


6/30

5 Cutting-edge Scientic FacilitiesMore than 90% o the ICRs laboratory estate has been built anew or reurbished over the last 10

years, ensuring that we have modern and ecient laboratories. The ICR has just completed a ve-

year programme during which we invested over 8 million in new scientic initiatives involving the

recruitment o additional world-class researchers to our aculty and the purchase o state-o-the-art

equipment.

6 Ability to Conduct Translational ResearchClose collaboration between our Research Sectionsand our partnership withThe Royal Marsden

enhances our ability to translate research ndings into patient benet. In the last 10 years, the ICR

has taken 10 cancer drugs into clinical trials, an achievement unmatched anywhere in the world.

7 On-site Sport and Social FacilitiesOur Student Committeeorganises a range o on-site sporting and social activities to connect

students across both our sites:

ChelseaOur central-London location provides easy access to a huge variety o caes, bars and restaurants as well

as countless historical and modern attractions. We run a number o sports clubs on a regular basis, such

as a highly successul cricket team.

SuttonWe ofer a range o on-site sporting acilities including a swimming pool, gym, and tennis and squash

courts. Sports clubs include yoga, karate, circuit training and ultimate Frisbee. During the summer, we

hold a Mini-Olympics, which sees mixed teams competing against each other in a variety o sportsincluding swimming, squash, table tennis and video games! Traditionally, our students organise a

barbeque to celebrate the sporting event at the Finals Night.

pH BarThe pH bar, located at our Sutton site, is open every Thursday and Friday and has cheap drinks, pool and

snooker tables, dart board and table ootball. All ICR staf have access to the bar, which is run entirely by

student and staf volunteers.

http://www.icr.ac.uk/research/research_sections/index.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/education/education_strategy/student_committee/index.shtmlhttp://www.icr.ac.uk/education/education_strategy/student_committee/index.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_sections/index.shtml


7/30

The diversity o our students enriches academic andsocial lie at the ICR; we have students rom all over the

world. China, Greece, India, Israel, Korea and Spain are justa ew o the countries represented.

8 Access to Tailored ResourcesWe have award-winning resources or PhD students written by our Interactive Education Unit:

Perspectives in Oncology - the cancer science website and a Study Skills website.

9 Comprehensive Learning and DevelopmentWe provide a wide range o orums and activities to support the personal and proessional

development o our students. These include research group seminars, the ICRs AnnualConerence, an extensive guest seminar programme and a Science Communication Course.

Students are also encouraged and supported to attend and present at national and international

conerences, such as AACR. We provide all our students with 10 days personal development

per annum.

10 More than an EducationThe diversity o our students enriches academic

and social lie at the ICR; we have students rom

all over the world. China, Greece, India, Israel,

Korea and Spain are just a ew o the

countries represented. We not only provideour students with irst-class scientiic

training but also the opportunity to make

lie-long riends and meet potential

scientiic collaborators.



8/30

Meet The Student President

Jamie MallinsonJamie began his PhD entitled Functionalised Macrocycles as Scafolds orthe Discovery o Novel Protein Kinase Inhibitors at the ICR in 2009 under thesupervision oDr Ian Collins in theCancer Research UK Cancer TherapeuticsUnit. In January 2010, Jamie was voted Student President o the ICR StudentCommittee; he is also a student representative on the Ups Club committee.

Ater spending time in industry labs as an undergraduate, Jamies

comparative impression o the acilities and research at the ICR helped

make his decision to apply or his PhD. The labs at the ICR are o the

highest standard, and are comparable to those ound in industry. They

are very well equipped and have the latest technologies he explains.

Jamie was impressed by the scope o research being undertaken at the ICR: I think being exposedto both academic research and drug discovery at the ICR really prepares you or the uture.

Along with his challenging PhD project, Jamie has taken on the responsibilities o Student

President where he makes sure that the student opinion is listened to. Since being voted into the

role by other students in the annual elections, he has organised and chaired various meetings or

the Student Committee the student run organisation which mediates communication between

students and the ICR.

The Student Committee represents all students at the ICR, and is involved in decision making at all

levels, Jamie explains. The Committee is always involved in major decisions that aect students.

For example, we were involved in the discussions and debates about the introduction o plagiarismdetection sotware.

There is regular eedback between the StudentCommittee and the ICR in order to continually improvethe standard o our education.As well as helping students to have their say on academic matters, Jamie helps coordinate the

sports and social activities available at the ICRs Ups Club, including the Mini-Olympics Finals night

party: There are many students rom varied backgrounds, and all are really r iendly. We have loads

o great scientiic discussions, but also a lot o un socially.

http://www.icr.ac.uk/research/research_profiles/4506.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/4506.shtml


9/30

Meet Our Alumni

Dr Katy EverettKaty graduated rom the ICR in 2009 with a PhD gained under thesupervision oDr Matilda Katan in the Section o Cell and MolecularBiology. She currently works within the Department o Pharmacologyat the University o Cambridge as a Postdoctoral Research Associate,specialising in cross-talk between calcium and cyclic AMP signallingpathways.

Katys application to the ICR ollowed an interest in her PhD title, Molecular

Mechanisms o Regulation in Phospholipase C gamma enzymes, and Dr Matilda

Katansresearch in the Lipid Signalling Team. She was urther attracted by the ICRs

research reputation, acilities and the city setting o the Chelsea site.

Katy ound her project, which was investigating mutations o the Phospholipase C gamma enzymes (PLC

gamma), both challenging and stimulating: The PLC gamma enzymes, PLC gamma 1 and PLC gamma 2,

are activated downstream o receptor and non-receptor tyrosine kinases. PLC gamma 1 has a role in cell

motility and may act as a common rate limiting step in cancer cell motility downstream rom activated

growth actors and integrins. PLC gamma 2 expression is highest in blood cells and disrupting normal PLC

gamma 2 unction in mice results in a phenotype with similarities to human immune diseases. Although

the pathways that activate PLC gamma isoorms have been well studied, the molecular mechanisms

involved in their regulation through auto-inhibition and activation are not well dened. We introduced a

variety o mutations to PLC gamma 1 and PLC gamma 2 domains to investigate the mechanisms involved

in regulation. Observations supported the idea that the catalytic domain, and a group o domains known

as the specic array, are essential or regulation o PLC gamma activity. The mutants we described mayprove to be useul tools or studying signalling networks involving PLC gamma isoorms.

Throughout her PhD, Katy was supported by both her supervisor and the other enthusiastic

researchers in her lab: Dr Katan made time to discuss students projects with them and was

particularly helpul in giving eedback when it was time to write up.

I would recommend the ICR as a supportive andwell-unded place to do a PhD.Outside o her project, Katy enjoyed the social activities on oer to students, and was a member o

the student committee or two years and a student representative on the Academic Board.

Following her time at the ICR, Katy has ound that the research she carried out has been invaluable

in developing her career: During my PhD I was able to contribute to various papers, which really

opened up more options when applying or postdoctoral jobs.

http://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/lipid_signalling/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/lipid_signalling/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtml


10/30

Dr Matthew GoldMatthew graduated rom the ICR with a PhD in 2007 under the supervision oProessor David Barord in the Section o Structural Biology. He is now on anoverseas research adventure in Seattle as a Sir Henry Wellcome Postdoctoral

Research Fellow. He specialises in the regulation o signalling by scafoldproteins.

Matthew became interested in structural biology during his time as an

undergraduate at Cambridge. In his nal year, he searched or the best

structural biology lab in the UK in which to pursue this interest. My

undergraduate research project advisor recommended the Structural Biology department at the ICR. I

was attracted by my supervisors research, the PhD topic and the unique acilities. Plus, I was impressed

by the antastic quality o research taking place within the other ICR sections.

Ater a successul application, Matthew went on to investigate a class o signal-organising proteins

called A-Kinase Anchoring Proteins (AKAPs): AKAPs direct the action o protein kinase A (PKA),which is a critical regulator o many biological processes, including cell growth, heart rate and

memory ormation.

In the course o my research, I solved the three-dimensional structure o the key PKA-AKAP interace,

which establishes the molecular basis or PKA anchoring. I also determined another crystal structure,

which revealed that one AKAP (AKAP18) can bind to the small molecule AMP this was an unexpected

clue to its unction.

Matthew ound his supervisor to be supportive, encouraging and knowledgeable: David was brilliant

at answering my questions, he allowed me reedom to explore my ideas, and his dedication and

enthusiasm or science set an excellent example. I used some o my unding to pay or a distance-

learning qualiication in Protein Crystallography, to also attend conerences and to oster overseascollaborations.

One o my lasting memories as an ICR graduate student isstumbling out o the synchrotron acility in Grenoble in theearly hours o the morning in pitch darkness under heavysnowall we solved the AKAP18 crystal structure on thattrip!

http://www.icr.ac.uk/research/research_profiles/2958.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2958.shtml


11/30

Our Research SectionsThe Breakthrough Toby Robins Breast Cancer ResearchCentre

Director: Proessor Alan Ashworth FRSThe Breakthrough Breast Cancer Research Centre supports a programme

o cutting-edge biological research to tackle breast cancer, to discover

the causes o the disease, nd methods o prevention, and develop new

treatments and more efective methods or diagnosis. The Centre has very

good interactions with those involved in breast cancer patient care in

The Royal Marsden. The Centre has signicant core acilities and a very active

programme o seminars and meetings.

Apoptosis Proessor Pascal Meier

Cancer Inormatics Dr Marketa Zvelebil

Drug Target Discovery Dr Spiros Linardopoulos

Gene Function Proessor Alan Ashworth FRS

Mammary Stem Cells Dr Matthew Smalley

Molecular Cell Biology Proessor Clare Isacke

Molecular Pathology Dr Jorge Reis-Filho

Endocrinology Proessor Mitch Dowsett

The Breakthrough Breast Cancer Research Centre at theICR supports a programme o cutting-edge biologicalresearch to tackle breast cancer, to discover the causes othe disease, nd methods o prevention, and develop newtreatments and more efective methods or diagnosis.

http://www.icr.ac.uk/research/research_sections/breakthrough/index.shtmlhttp://www.icr.ac.uk/research/research_sections/breakthrough/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/3934.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/apoptosis/index.htmlhttp://www.icr.ac.uk/research/research_profiles/3930.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/cancer_informatics/index.htmlhttp://www.icr.ac.uk/research/research_profiles/7218.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/drug_target_discovery/index.htmlhttp://www.icr.ac.uk/research/research_profiles/2782.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/gene_function/index.htmlhttp://www.icr.ac.uk/research/research_profiles/3934.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/mammary_stem_cells/index.htmlhttp://www.icr.ac.uk/research/research_profiles/4188.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/molecular_cell_biology/index.htmlhttp://www.icr.ac.uk/research/research_profiles/3469.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/molecular_pathology/index.htmlhttp://www.icr.ac.uk/research/research_profiles/4190.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/endocrinology/index.htmlhttp://www.icr.ac.uk/research/research_profiles/2737.shtmlhttp://www.icr.ac.uk/research/research_profiles/2737.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/endocrinology/index.htmlhttp://www.icr.ac.uk/research/research_profiles/4190.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/molecular_pathology/index.htmlhttp://www.icr.ac.uk/research/research_profiles/3469.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/molecular_cell_biology/index.htmlhttp://www.icr.ac.uk/research/research_profiles/4188.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/mammary_stem_cells/index.htmlhttp://www.icr.ac.uk/research/research_profiles/3934.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/gene_function/index.htmlhttp://www.icr.ac.uk/research/research_profiles/2782.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/drug_target_discovery/index.htmlhttp://www.icr.ac.uk/research/research_profiles/7218.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/cancer_informatics/index.htmlhttp://www.icr.ac.uk/research/research_profiles/3930.shtmlhttp://www.breakthroughresearch.org.uk/the_research_centre/research_teams/apoptosis/index.htmlhttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_profiles/3934.shtmlhttp://www.icr.ac.uk/research/research_sections/breakthrough/index.shtmlhttp://www.icr.ac.uk/research/research_sections/breakthrough/index.shtml


12/30

Section o Gene Function & RegulationChairman: Proessor Peter Rigby FRS

The overall strategy o the Section o Gene Function and Regulation is

to pursue basic research into normal developmental and diferentiation

processes and gain insight into the underlying mechanisms at the levelo gene expression and also chromatin structure. This research is the

prerogative o basic biological science and, since many o the genes that

are disrupted or dysregulated in cancer are regulators o developmental

and diferentiation processes, this programme o work is likely to provide

signicant insight into cancer mechanisms. The Section particularly ocuses

on pathways, systems or processes with obvious cancer relevance.

Molecular Embryology Proessor Peter Rigby FRS

Sexual Development Dr Amanda Swain

Section o Structural BiologyJoint Chairmen: Proessor David Barord FRS& Proessor Dale Wigley FRSResearch teams in the Section o Structural Biology apply techniques o

X-ray crystallography, electron microscopy, biophysics, biochemistry and

molecular biology to understand the structural basis or the unction and

regulation o proteins and complexes implicated in cancer. Our programmes

cover a range o key molecular systems and processes, including signal

transduction, cell-cycle control, transcriptional regulation, targeted protein

destruction,chaperone unction, DNA repair, chromatin modication and

chromosome dynamics. In addition to our basic science programmes, we maintain close links with groups in

the ICR and beyond, in order to develop new therapeutics targeted at these systems using structure-based

drug design.

Barord Group Proessor David Barord FRS

Wigley Group Proessor Dale Wigley FRS

Chromatin Regulation Dr Jon WilsonMitotic Regulation & Cancer Dr Richard Bayliss

Structural Electron Microscopy Dr Ed Morris

Structure-based Drug Design Dr Robert van Montort

http://www.icr.ac.uk/research/research_sections/gene_function_and_regulation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2867.shtmlhttp://www.icr.ac.uk/research/research_sections/gene_function_and_regulation/gene_function_and_regulation_teams/molecular_embryology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2867.shtmlhttp://www.icr.ac.uk/research/research_sections/gene_function_and_regulation/gene_function_and_regulation_teams/sexual_devlopment/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2874.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2958.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/barford_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2958.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/chromatin_regulation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/8109.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/mitotic_regulation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/3747.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/structural_electron_microscopy/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2961.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/structure_based_drug_design/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7896.shtmlhttp://www.icr.ac.uk/research/research_profiles/7896.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/structure_based_drug_design/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2961.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/structural_electron_microscopy/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/3747.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/mitotic_regulation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/8109.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/chromatin_regulation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2958.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/teams/barford_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2958.shtmlhttp://www.icr.ac.uk/research/research_sections/structural_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2874.shtmlhttp://www.icr.ac.uk/research/research_sections/gene_function_and_regulation/gene_function_and_regulation_teams/sexual_devlopment/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2867.shtmlhttp://www.icr.ac.uk/research/research_sections/gene_function_and_regulation/gene_function_and_regulation_teams/molecular_embryology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2867.shtmlhttp://www.icr.ac.uk/research/research_sections/gene_function_and_regulation/index.shtml


13/30

Section o Cell & Molecular Biology (including the CancerResearch UK Tumour Cell Signalling Unit)Chairman: Proessor Chris Marshall FRSDeputy Chairman: Proessor Richard Marais

The Section o Cell and Molecular Biology encompasses a wide range

o activities, rom studies o gene therapy o cancer to studies on the

mechanism o protein olding. This range o activities reects the underlying

approach o studying basic molecular and cell biology to underpin the

identication o new strategies or cancer therapeutics. A signicant element

o the work in the Section is unded through the Cancer Research UK Programme on Tumour Cell

Signalling Networks. Much o the research in the Section ocuses on the molecular dissection o cancer

genes and how this afects cell signalling. A new initiative within the Section is systems biology, where we

exploit computational biology and network based analysis to understand signalling in tumours.

Antioncogene Proessor Sybille Mittnacht

Cell Communication Dr Claus Jorgensen

Cellular & Molecular Logic Dr Rune Linding

Dynamical Cell Systems Dr Chris Bakal

Hypoxia & Metastasis Dr Janine Erler

Lipid Signalling Dr Matilda Katan

Oncogene Team Proessor Chris Marshall FRS

Protein Folding & Assembly Proessor Keith WillisonProtein Networks Dr Paul Huang

Signal Transduction Proessor Richard Marais

Targeted Therapy Dr Kevin Harrington

The Section o Cell and Molecular Biology encompassesa wide range o activities, rom studies on gene therapy o

cancer to studies on the mechanism o protein olding.

http://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2838.shtmlhttp://www.icr.ac.uk/research/research_profiles/2856.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/antioncogene/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2840.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/cell_communication_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/14826.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/network_syst_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7882.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/dynamical_cell_systems/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/14201.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/hypoxia_metastasis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7901.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/lipid_signalling/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/oncogene/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2838.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/protein_folding%20_and%20_assembly/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2854.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/protein_networks/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/12273.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/signal_transduction/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2856.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/targeted_therapy/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2858.shtmlhttp://www.icr.ac.uk/research/research_profiles/2858.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/targeted_therapy/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2856.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/signal_transduction/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/12273.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/protein_networks/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2854.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/protein_folding%20_and%20_assembly/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2838.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/oncogene/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2848.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/lipid_signalling/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7901.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/hypoxia_metastasis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/14201.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/dynamical_cell_systems/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7882.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/network_syst_biology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/14826.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/cell_communication_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2840.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/cell_and_mol_biology_teams/antioncogene/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2856.shtmlhttp://www.icr.ac.uk/research/research_profiles/2838.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cell_and_molecular_biology/index.shtml


14/30

Cancer Research UK Cancer Therapeutics Unit

Section Chairman& Centre Director: Proessor Paul Workman

Deputy Chairman/Director& Head o Chemistry: Proessor Julian Blagg

The Cancer Research UK Cancer Therapeutics Unit is a unique academic drug

discovery group. Its mission is to discover novel and efective small molecule

therapeutics or the treatment o cancer.

Primary aims include:

To identify and validate novel genes and pathways as targets for therapeutic intervention in cancer

To implement innovative technologies for drug discovery

By these means, to discover novel mechanism-based preclinical drug candidates and to progress

these as rapidly as possible rom the laboratory through to hypothesis-testing early clinical trials As a result, to contribute to the improved treatment of human cancers

Cell Cycle Control Dr Michelle Garrett

Clinical Pharmacology & Trials Proessor Ian Judson & Dr Udai Banerji

Computational Biology & Chemogenomics Dr Bissan Al-Lazikani

Gene & Oncogene Targeting Proessor Caroline Springer

Medicinal Chemistry Team One Proessor Julian Blagg

Medicinal Chemistry Team Two Dr Ian CollinsMedicinal Chemistry Team Three Proessor Keith Jones

Medicinal Chemistry Team Four Dr Swen Hoelder

Signal Transduction & Molecular Pharmacology Proessor Paul Workman

Hit Discovery & Structural Design Dr Rob van Montort

Target Discovery & Apoptosis Dr Spiros Linardopoulos

Tumour Biology & Metastasis Dr Suzanne Eccles

http://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2773.shtmlhttp://www.icr.ac.uk/research/research_profiles/7879.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/cell_cycle_control/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2774.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/clinical_pharmacology_and_trials/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2825.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/comp_bio_chemogen/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/10480.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/gene_and_oncogene_targeting/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2799.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry1/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7879.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry2/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/4506.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry3/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2797.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry4/6585.shtmlhttp://www.icr.ac.uk/research/research_profiles/7880.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/signal_transduction_and_molecular_pharmacology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2773.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/hit_discovery_structural_design/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7896.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/target_discovery_and_apoptosis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2782.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/tumour_biology_and_metastasis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2800.shtmlhttp://www.icr.ac.uk/research/research_profiles/2800.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/tumour_biology_and_metastasis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2782.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/target_discovery_and_apoptosis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7896.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/hit_discovery_structural_design/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2773.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/signal_transduction_and_molecular_pharmacology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7880.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry4/6585.shtmlhttp://www.icr.ac.uk/research/research_profiles/2797.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry3/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/4506.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry2/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7879.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/medicinal_chemistry1/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2799.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/gene_and_oncogene_targeting/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/10480.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/comp_bio_chemogen/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_profiles/2825.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/clinical_pharmacology_and_trials/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2774.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/cancer_therapeutics_teams/cell_cycle_control/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7879.shtmlhttp://www.icr.ac.uk/research/research_profiles/2773.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtml


15/30

Cancer Research UK/Engineering & Physical SciencesResearch Council (EPSRC) Imaging CentreJoint Chairmen: Proessors Martin Leach& Nandita deSouzaFacilities in the Cancer Research UK/EPSRC Cancer Imaging Centre are

primarily ocused on Clinical Magnetic Resonance (MR), and include: two

clinical 1.5-T MR scanners, a 3T clinical scanner, together with 7-T and

11.7-T experimental systems, and a urther 11.7T system being installed.

The primary research ocus has been on dening the role o MR in cancer

diagnosis, staging, and response assessment.

Other unctional methods are being developed, including preclinical

Positron Emission Tomography-Computed Tomography (PET-CT)

(equipment currently being commissioned) and experimental optoacoustic

imaging. These techniques are being evaluated in a multimodality

approach as prognostic and therapeutic biomarkers, particularly or

determining the action o and response to novel therapeutic agents. All

approaches are increasingly using quantitative methodologies. The Section

is also developing and assessing novel imaging methods or radiotherapy

planning, developing improved analysis or breast cancer, and exploring

basic technologies such as dynamic nuclear polarisation. The Section has

provided analysis methods to academic centres and industry, and has reported methods in cancer.

Imaging Proessors Martin Leach/

Nandita deSouza

Section o Epidemiology

Chairman: Proessor Anthony Swerdlow

The Section o Epidemiology is involved in studies o the aetiology o cancer,

cancer genetics and occupational epidemiology. There is a particular ocus

on breast cancer, but also substantial work on several other cancers including

brain tumours, leukaemia, cervical cancer and mesothelioma. Several large

cohort studies are being undertaken, including the Breakthrough Generations

Study in collaboration with the Breakthrough Breast Cancer Research Centre.Our genetic studies are carried out in collaboration with the Section o

Cancer Geneticsand the Academic Department o Biochemistry. Several o our studies are conducted in

collaboration with the London School o Hygiene and Tropical Medicine.

Aetiological Epidemiology Proessor Anthony Swerdlow

Molecular Epidemiology Proessor Monste Garcia-Closas

http://www.icr.ac.uk/research/research_sections/magnetic_resonance/index.shtmlhttp://www.icr.ac.uk/research/research_sections/magnetic_resonance/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2860.shtmlhttp://www.icr.ac.uk/research/research_profiles/2861.shtmlhttp://www.icr.ac.uk/research/research_sections/magnetic_resonance/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2860.shtmlhttp://www.icr.ac.uk/research/research_profiles/2861.shtmlhttp://www.icr.ac.uk/research/research_sections/epidemiology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2863.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_genetics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_genetics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_genetics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/biochemistry/index.shtmlhttp://www.lshtm.ac.uk/http://www.icr.ac.uk/research/research_sections/epidemiology/epidemiology_teams/aetiological_epidemiology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2863.shtmlhttp://www.icr.ac.uk/research/research_profiles/2863.shtmlhttp://www.icr.ac.uk/research/research_sections/epidemiology/epidemiology_teams/aetiological_epidemiology/index.shtmlhttp://www.lshtm.ac.uk/http://www.icr.ac.uk/research/research_sections/biochemistry/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_genetics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_genetics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2863.shtmlhttp://www.icr.ac.uk/research/research_sections/epidemiology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2861.shtmlhttp://www.icr.ac.uk/research/research_profiles/2860.shtmlhttp://www.icr.ac.uk/research/research_sections/magnetic_resonance/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2861.shtmlhttp://www.icr.ac.uk/research/research_profiles/2860.shtmlhttp://www.icr.ac.uk/research/research_sections/magnetic_resonance/index.shtmlhttp://www.icr.ac.uk/research/research_sections/magnetic_resonance/index.shtml


16/30

Joint Department o PhysicsSection Chairman: Proessor Steve Webb

The mission o the Joint Department o Physics, which spans bothThe Royal

Marsden and the ICR, is to develop and apply techniques or cancer diagnosis

and treatment. Within The Royal Marsden, the major roles o the Departmentare to provide support or the clinical activities o radiotherapy, nuclear

medicine and radiology and to manage a radiation protection service.

Within the ICR, the Section pursues a research and postgraduate teaching

programme. Major research areas include: conormal, intensity-modulated

radiation therapy, image-guided radiotherapy, radiopharmaceutical

development, biologically targeted radionuclide therapy, high-ocused ultrasound therapy, ultrasound

and X-ray imaging, detector development and diagnostic imaging. The Department conducts research

into physics as applied to medicine and then acts as the translator o this research into clinical practice.

Clinical Radiotherapy Physics (Fulham) Miss Margaret Bidmead

Clinical Radiotherapy Physics (Sutton) Mr Jim Warrington

Radioisotope Physics Dr Glenn Flux

Radiological Physics Mr Jim Thurston

Radiotherapy Physics Proessor Steve Webb/Dr Phil Evans/

Dr Mike Partridge

Multimodal Molecular Imaging Dr Dimitra Darambara

Therapeutic Ultrasound Dr Gail ter Haar

Ultrasound & Optical Imaging Dr Jefrey Bamber

The mission o the Joint Department o Physics, whichspans both The Royal Marsden and the ICR, is to developand apply techniques or cancer diagnosis and treatment.

http://www.icr.ac.uk/research/research_sections/physics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2934.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_sections/physics/teams/clinical_radiotherapy_fulham/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/clinical_radiotherapy_fulham/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/clinical_radiotherapy_sutton/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/clinical_radiotherapy_sutton/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/radioisotope_physics_/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/radiological_physics_/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/radiotherapy_physics_research_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2934.shtmlhttp://www.icr.ac.uk/research/research_profiles/4591.shtmlhttp://www.icr.ac.uk/research/research_profiles/7750.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/therapeutic_ultrasound_/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2938.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/ultrasound_and_optical_imaging_/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2939.shtmlhttp://www.icr.ac.uk/research/research_profiles/2939.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/ultrasound_and_optical_imaging_/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2938.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/therapeutic_ultrasound_/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7750.shtmlhttp://www.icr.ac.uk/research/research_profiles/4591.shtmlhttp://www.icr.ac.uk/research/research_profiles/2934.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/radiotherapy_physics_research_team/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/radiological_physics_/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/radioisotope_physics_/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/clinical_radiotherapy_sutton/index.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/teams/clinical_radiotherapy_fulham/index.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_profiles/2934.shtmlhttp://www.icr.ac.uk/research/research_sections/physics/index.shtml


17/30

Section o Academic Radiotherapy & Department oRadiotherapy (including Psychology Research Group)Chairman: Proessor Alan Horwich

The main research theme o the Section o Radiotherapy is the development

and application o radiotherapy techniques, and there is extensive

collaboration with the Joint Physics Department. Current themes include:

applications o unctional imaging; assessment o image guidance,

such as with cone-beam Computed Tomography (CT) or Calypso seeds;

developments in delivery including Volumetric Modulated Arc Therapy

(VMAT) and Cyberknie.

New methods o external beam radiation require research relating to denition o target volumes,

quantication o benets rom rened treatment planning methods (including dose-volume toxicity

modelling), implementation and assessment o radiation beam delivery techniques, and careul quality

assurance to ensure the saety o new techniques in a clinical context. Alongside applications o physics

research, we investigate possible drug-radiation synergies. Our research aims to improve radiotherapy in

selected situations, to optimise techniques and to evaluate the benet o these approaches to the health

service.

Bladder Cancer/Testicular Cancer Dr Robert Huddart

Breast Cancer Proessor John Yarnold

Head & Neck Cancers Dr Christopher Nutting

Lung/CNS Tumours Proessor Michael Brada

Prostate Cancer Proessor David DearnaleyProstate Cancer Dr Christopher Parker

Psychology Research Group Dr Maggie Watson

Testicular Cancer/Lymphomas Proessor Alan Horwich

Section o Clinical TrialsChairman: Proessor Judith Bliss

The Clinical Trials and Statistics Unit (ICR-CTSU) was established in the 1980s

at the ICR as part o the Section o Epidemiology. In January 2004, the

ICR-CTSU was established as an independent research section (Section oClinical Trials) in recognition o its growth and National Cancer Research

Institute (NCRI) accreditation. The main objective o the ICR-CTSU is to design,

initiate, conduct and analyse national and international randomised clinical trials

o cancer treatment which will directly inuence routine clinical practice within

the National Health Serviceand worldwide.

Clinical Trials & Statistics Unit (ICR-CTSU) Proessor Judith Bliss

Deputy Director - Research Dr Emma Hall

Deputy Director - Operations Miss Claire Snowdon

http://www.icr.ac.uk/research/research_sections/radiotherapy/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2941.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/bladder_research/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2948.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2944.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2950.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2954.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2955.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/teams/Psychology%20Research%20Group%20Home/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2941.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_trials/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2859.shtmlhttp://www.icr.ac.uk/research/research_sections/epidemiology/index.shtmlhttp://www.nhs.uk/Pages/HomePage.aspxhttp://www.nhs.uk/Pages/HomePage.aspxhttp://www.icr.ac.uk/research/research_sections/clinical_trials/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2859.shtmlhttp://www.icr.ac.uk/research/research_profiles/2859.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_trials/index.shtmlhttp://www.nhs.uk/Pages/HomePage.aspxhttp://www.icr.ac.uk/research/research_sections/epidemiology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2859.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_trials/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2941.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/teams/Psychology%20Research%20Group%20Home/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2955.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2954.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2950.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2944.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/clinical_projects/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2948.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/uro_test_research/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/bladder_research/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2941.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/index.shtmlhttp://www.icr.ac.uk/research/research_sections/radiotherapy/index.shtml


18/30


19/30

Section o Haemato-oncologyChairman: Proessor Mel Greaves FRS

The Section o Haemato-oncology is an integrated Section that brings

together basic laboratory research, molecular diagnostics and treatment

o the blood cell cancers o adults and children (acute and chronicleukaemias, lymphomas and myeloma).

The Sections major objectives are:

To uncover the molecular mechanisms underlying the pathogenesis of

leukaemias, lymphomas and myeloma (i.e. the blood cell cancers)

To apply this knowledge to achieve two practical goals: (a) to advance our

understanding o the aetiology o leukaemia leading in the long term to the introduction o

preventive measures and (b) to improve the management o patients via the development o

new molecular tools or dierential diagnosis, prognosis, monitoring and treatment

Biology o Childhood Leukaemia Proessor Mel Greaves FRS

Leukaemia & Myeloma Molecular Genetics Proessor Gareth Morgan

Myeloma Targeted Treatment Dr Faith Davies

Stem Cells & Chromatin Dr Tomoyuki Sawado

Transcriptional Controls in Leukaemia Dr Arthur Zelent

The Section o Haemato-oncology is an integratedSection that brings together basic laboratory research,molecular diagnostics and treatment o the blood cellcancers o adults and children.

http://www.icr.ac.uk/research/research_sections/haemato_oncology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2875.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/aetiology_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2875.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/molecular_haematology_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2885.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/myeloma_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2896.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/stem_cells_chromatin/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/9632.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/transcriptional_controls/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2892.shtmlhttp://www.icr.ac.uk/research/research_profiles/2892.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/transcriptional_controls/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/9632.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/stem_cells_chromatin/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2896.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/myeloma_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2885.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/molecular_haematology_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2875.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/haemato_oncology_teams/aetiology_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2875.shtmlhttp://www.icr.ac.uk/research/research_sections/haemato_oncology/index.shtml


20/30

Section o MedicineChairman: Proessor Stan Kaye

The Section o Medicine has the ollowing major spheres o activity:

Joint responsibility (with the Cancer Research UK Cancer TherapeuticsUnit) or the Drug Development Unit, based atThe Royal Marsden. The

clinical acility is housed in Oak Ward, and the total staf is more than 80.

The Unit sees upwards o 500 patients per year or new drug treatment,

and with around 30 open trials at any one time, it is one o the largest

such units in the world. Senior investigators are Proessor Stan Kaye,

Dr Johann de Bono, Dr Udai Banerjiand Dr Rhoda Molie

A laboratory programme focused on drug discovery and development in ovarian cancer. Proessor

Robert Brown(joint appointment with Imperial College) leads a team in conjunction with Proessor

Stan Kayeaiming to identiy new orms o epigenetic therapy in the context o drug resistant disease

A translational research programme, in conjunction with the Drug Development Unit, ocusing on

identiying cancer biomarkers in the context o new drug evaluation. This is led by Dr Johann de

Bono, who also has a specic interest in prostate cancer (utilising circulating tumour cells)

An integrative programme of core clinical fellows, linking the Section of Medicine to other ICR

Sections. These comprise clinical ellows in ovarian cancer drug development (supervised by

Proessor Stan Kaye, Dr Udai Banerji and Proessor Paul Workman o theCancer Research UK Cancer

Therapeutics Unit); and in prostate cancer (supervised by Dr Johann de Bonoand Proessor Colin

Cooperin the Prostate Collaborative)

Breast Cancer Proessor Ian Smith/

Proessor Stephen Johnston

Gastrointestinal Cancer Proessor David Cunningham

Lung Cancer Dr Mary OBrien

Sarcoma Proessor Ian Judson

Melanoma/Renal/Gynaecological Cancer Proessor Martin Gore

Prostate Cancer/Drug Evaluation Dr Johann de Bono

Gynaecological Cancer/Drug Evaluation Proessor Stan Kaye

Drug Evaluation Dr Udai Banerji

Epigenetics Proessor Robert Brown

/Dr Rhoda Molie

http://www.icr.ac.uk/research/research_sections/medicine/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/5734.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_profiles/7565.shtmlhttp://www.icr.ac.uk/research/research_profiles/7565.shtmlhttp://www3.imperial.ac.uk/http://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/5734.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_profiles/2773.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/prostate_cancer_team/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/breast_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/gastrointestinal_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/lung_cancer_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/sarcoma_unit/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2825.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/skin_cancer_&_melanoma_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/gynaecology_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/prostate_cancer_team/index.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/drug_evaluation_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/gynaecology_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/drug_evaluation_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/drug_evaluation_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/epigenetics_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7565.shtmlhttp://www.icr.ac.uk/research/research_profiles/7565.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/epigenetics_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/drug_evaluation_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/drug_evaluation_team/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/gynaecology_unit/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/drug_evaluation_team/index.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/prostate_cancer_team/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/gynaecology_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/skin_cancer_&_melanoma_unit/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2825.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/sarcoma_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/lung_cancer_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/gastrointestinal_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/clinical_research/clinical_research_teams/breast_unit/index.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/teams/prostate_cancer_team/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2773.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/5734.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www3.imperial.ac.uk/http://www.icr.ac.uk/research/research_profiles/7565.shtmlhttp://www.icr.ac.uk/research/research_profiles/7565.shtmlhttp://www.icr.ac.uk/research/research_profiles/7220.shtmlhttp://www.icr.ac.uk/research/research_profiles/2904.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_sections/medicine/5734.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_sections/cancer_therapeutics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2898.shtmlhttp://www.icr.ac.uk/research/research_sections/medicine/index.shtml


21/30

Section o Molecular CarcinogenesisChairman: Proessor Colin CooperA major theme o the work o the Section is the application o the latest

molecular biological technologies to clinical problems identiied through

our links withThe Royal Marsden. Genomic inormation and newtechnologies generated rom the Cancer Genome Project have extended

the ocus to include research into identiying new prognostic and

diagnostic markers that may be o use in the management o sarcomas

and cancer o the prostate and testis. Agents potentially responsible or

many human cancers are still to be identiied, and a major objective o

Proessor David Phillips team is to identiy new classes o chemicals that may contribute to cancer

development. Dr Janet Shipleycollaborates closely with colleagues rom theSection o Paediatric

Oncologyto utilise ully the increasing amount o high quality genetic inormation that is becoming

available rom theHuman Genome Project.

Cell Transormation Proessor Colin Cooper

Human Biomonitoring & Carcinogen Activation Proessor David Phillips

Molecular Cytogenetics Dr Janet Shipley

A major theme o the work o the Section o MolecularCarcinogenesis is the application o the latest molecular

biological technologies to clinical problems identiedthrough our links with The Royal Marsden.

http://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_profiles/2912.shtmlhttp://www.icr.ac.uk/research/research_profiles/2914.shtmlhttp://www.icr.ac.uk/research/research_sections/paediatric_oncology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/paediatric_oncology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/paediatric_oncology/index.shtmlhttp://www.genome.gov/10001772http://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/molecular_carcinogenesis_teams/cell_transformation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/molecular_carcinogenesis_teams/human_biomonitoring_carcinogen_activation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2912.shtmlhttp://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/molecular_carcinogenesis_teams/molecular_cytogenetics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2914.shtmlhttp://www.icr.ac.uk/research/research_profiles/2914.shtmlhttp://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/molecular_carcinogenesis_teams/molecular_cytogenetics/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2912.shtmlhttp://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/molecular_carcinogenesis_teams/human_biomonitoring_carcinogen_activation/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/molecular_carcinogenesis_teams/cell_transformation/index.shtmlhttp://www.genome.gov/10001772http://www.icr.ac.uk/research/research_sections/paediatric_oncology/index.shtmlhttp://www.icr.ac.uk/research/research_sections/paediatric_oncology/index.shtmlhttp://www.icr.ac.uk/research/research_profiles/2914.shtmlhttp://www.icr.ac.uk/research/research_profiles/2912.shtmlhttp://www.royalmarsden.nhs.uk/homehttp://www.icr.ac.uk/research/research_profiles/2911.shtmlhttp://www.icr.ac.uk/research/research_sections/molecular_carcinogenesis/index.shtml


22/30

Our Campus

Chelsea SiteLondon has a packed programme o estivals andevents running throughout the year, together

with museums, art galleries and concert halls,

West End theatres and cinemas, restaurants,

pubs, clubs and bars, catering or all tastes. It

is the centre o politics and government with

many amous landmarks, including the Houses

o Parliament, St Pauls Cathedral, Buckingham

Palace, the Royal Albert Hall, the Tower o London

and Westminster Abbey. There are beautiul and

surprisingly large green spaces, such as Hyde

Park, Regents Park, Hampstead Heath and the

Botanical Gardens at Kew. The ICR is situated in

the heart o ashionable Chelsea with its designer

shops, bars and restaurants, only a stones throw

away rom the amous Kings Road and a short walk away rom the museums o South Kensington.

View a map and directions to the ICR at Chelsea

Sutton SiteOnly twelve miles rom central London, Sutton

is located in Surrey, close to the rolling NorthDowns. The historic towns o Guildord and

Kingston are nearby, and the south coast and the

popular resort o Brighton are only an hour away

by car. Sutton is a modern town with all the major

shops, together with restaurants, pubs, cinemas

and many amateur theatre and musical groups.

View a map and directions to the ICRat Sutton

http://www.icr.ac.uk/contact_us/chelsea/index.shtmlhttp://www.icr.ac.uk/contact_us/sutton/index.shtmlhttp://www.icr.ac.uk/contact_us/sutton/index.shtmlhttp://www.icr.ac.uk/contact_us/sutton/index.shtmlhttp://www.icr.ac.uk/contact_us/sutton/index.shtmlhttp://www.icr.ac.uk/contact_us/sutton/index.shtmlhttp://www.icr.ac.uk/contact_us/chelsea/index.shtml


23/30

Student Support and Resources

Academic SupportThe ICR has well-dened procedures or monitoring research student progress and provides support

and training to students and supervisors. The Academic Dean and his panel o advisors vet all projects.

All projects, regardless o the source o unding, must be underwritten by the Section Chair (Head o

Department) to ensure continuity.

Only members o the ICRs rigorously selected aculty are permitted to supervise students. Faculty

members are highly experienced project and resource managers who, nevertheless, are required

to undergo ormal training in supervision beore they take on research students, and also attend

periodic update sessions. All students also have a back-up supervisor and, in some cases, an associate

supervisor as well; the supervisors are collectively reerred to as the supervisory team. Supervisors

submit reports on the work o their students to the Deans Team at least once a year, highlighting any

problem areas i appropriate.

In years 1-3 students have an annual review with the Deputy Dean or a Senior Tutor to review progress;

in the nal year they have three monthly meetings with the Deputy Dean/Senior Tutor. A major review

is undertaken ater the end o the rst year, when the decision to transer rom MPhil to PhD is made.

Students submit a comprehensive report o between 2,000 and 3,000 words, including a critique o

the work already carried out and a discussion o the uture development o the project, and are then

examined orally by the supervisory team and an independent (internal) assessor. At 30 months (2 years

and 6 months), students submit a shorter report, and in the third year they submit a thesis plan.

Students are required to keep a portolio, which is a comprehensive record o their learning and

achievement, including any ormal training undertaken during their programme o study at the ICR.The detail o portolio content is agreed between the student and the supervisory team and the

portolio is reviewed by a member o the Deans Team as part o the annual monitoring process.

All students are provided with their skeleton portolio in their rst term.

Submission rates and external examiner reports are monitored by the ICRs Academic Committees.



24/30

Resources or Research StudentsThe ICRs Interactive Education Unit (IEU) has developed two educational websites to provide background

knowledge and training or all research degree students. Study Skills provides tips on transerable skills

in areas relevant to completing a scientic research degree, while Perspectives in Oncology provides athorough and connected grounding in relevant aspects o cancer science and treatment. These resources

provide sel-directed learning in areas not covered by lectures, and are designed or researchers to

complete at a convenient time and location. They are also designed to accommodate diferent levels o

understanding in a subject matter.

Study Skills websiteThis provides advice and guidance on a range o transerable skills relevant to study

or a research degree, but can also be applied in uture employment both inside and outside o the

laboratory setting. Topics include scientic writing, time management and organisational skills, preparing

and presenting seminars, critical reading, and understanding intellectual property.

Perspectives in Oncology - the cancer science website This gives students rom all academic backgroundsan overview o the eld o cancer science and provides an insight into how the various disciplines

together help reveal the nature o cancer, the mechanisms underlying its development and spread, and

how it can be managed, treated and prevented. Current modules are: Cancer causes and prevention;

Tumour genetics; Common cancers; An approach to therapies; Bioinormatics; Medical physics; Basics o

tumour biology and Cell signalling. Additional modules currently being written are Structural biology and

Experimental therapeutics.

Find out more about The Interactive Education Unit

http://studyskills-ieu.icr.ac.uk/index.aspxhttp://studyskills-ieu.icr.ac.uk/index.aspxhttp://perspectives.icr.ac.uk/pages/5492_your-account.aspxhttp://www.icr.ac.uk/education/education_strategy/ieu/index.shtmlhttp://www.icr.ac.uk/education/education_strategy/ieu/index.shtmlhttp://perspectives.icr.ac.uk/pages/5492_your-account.aspxhttp://studyskills-ieu.icr.ac.uk/index.aspx


25/30

Library and Inormation ServicesThe ICR has libraries on both sites, with 24-hour access available or registered users. Qualiied

library sta are available to help with any enquiries.

We have 5,000 electronic journal subscriptions, covering a number o specialist scientiic and

clinical ields, including biochemistry, chemistry, cell biology, genetics, pharmacology, oncology,

medical physics, immunology, surgery and anaesthetics. These can be accessed in the library, on

desktops throughout the ICR, or elsewhere. Where possible, physical copies o these journals are

also available, and the library has access to a growing number o electronic archives.

There are 5,000 books held between the two libraries -- covering all o the scientiic and clinical

research areas o interest -- and the library catalogue is available on the Internet. Online databases

and resources currently available or use both in the library and o-site include PubMed, Cochrane

Library, Faculty o 1000 Biology, Reaxys, Web o Knowledge and Zetoc. A series o online scientiic

lectures (the Henry Stewart Talks) is also available.

The libraries in both Chelsea and Sutton provide pleasant areas with numerous spaces or users to

browse the collections. In both libraries there are dedicated PhD study rooms, with PCs and printing

acilities available or readers, as well as plug sockets, network ports and wireless access or laptop

use.

Find out more about Library and Inormation Services

http://www.icr.ac.uk/education/education_strategy/icr_library/index.shtmlhttp://www.icr.ac.uk/education/education_strategy/icr_library/index.shtml


26/30

The RegistryThe Registry has responsibility or student-related administration, including:

Studentships

Recruitment and admissions Enrolment

Student records

Statutory reporting of student data

Student examinations and assessments/external examining

Degree Ceremony organisation

Developing higher education (HE) quality assurance and quality enhancement procedures

Servicing a number of academic and non-academic related committees

Servicing the Academic Deans meetings and business of the Academic Deans Team

Handling student cases Arranging conferences and lectures

Liaison with HE government agencies, the Quality Assurance Agency (QAA) and the University

o London

Involvement in taught course support, administration, teaching and learning

Registry sta are available to assist with queries or problems that may arise during your programme

o study

Learning and Development

The Learning and Development team provides a wide range o activities to support the personal andproessional development o students. These are based on the recommendations o the Research Councils

as to the key skills needed to build a successul research career - research skills and techniques, knowledge

o the research environment, research management, personal efectiveness, communication skills, team-

working, networking skills and career management.

We aim to provide all researchers with 10 days personal development per annum consisting o classroom

training courses, online learning, seminars on cutting-edge scientic techniques and work-based coaching.

We also provide internal and external careers advice and inormation to students.



27/30

Our Commitment to Equality and DiversityThe ICR promotes equality o opportunity in employment and teaching and opposes all orms o unlawul

discrimination on the grounds o any o the characteristics protected by law (race, sex, age religion or

belie, sexual orientation, disability, marriage or civil partnership, pregnancy and maternity, genderreassignment). The ICR also recognises that discrimination can arise rom other social actors, such as

caring responsibilities and personal background, and we are committed to creating an environment

where each individuals participation and advancement is based purely on merit.

The ICR will not tolerate discrimination by any o its staf or students. Unlawul discrimination and

harassment are regarded as gross misconduct and will be treated as a serious disciplinary matter.

Support or Disabled StudentsThe ICR aims to meet the needs o all students and considers each individual on academic merit. The

ICR has successully supported students with a range o disabilities and we take care to ensure that

inormation, advice and a support service are available to students who have welare or disability issues.The ICR has a student guide to disability services that outlines the support we ofer to students.

I you have any questions relating to your disability and studying at the ICR, you can contact the

Academic Registry at any stage in your application or advice and urther inormation.

The ICR aims to meet the needs o all students andconsiders each individual on academic merit.



28/30

CondentialityUnder the Data Protection Act 1998, any

inormation you disclose regarding your

disability and/or additional needs will be dealtwith in the strictest condence and inormation

about your disability will not be passed on

without your specic consent. Please bear in

mind that without knowledge o your disability,

it may be dicult to ully support your needs

and make the necessary adjustments. As

the ICR is predominantly a laboratory-based

environment, it is important that students who

work in a laboratory inorm their tutors o any

relevant medical condition or health and saety

purposes.

Data ProtectionThe ICR is committed to responsible data

processing in accordance with its legal

obligations as a data controller under The Data

Protection Act 1998 (the Act) and associated

codes o practice issued by the Inormation

Commissioner. Our policy aims to ensure that

all individuals about whom the ICR processes

data are properly inormed about the eect

o the Act in respect o both their rights and

their obligations.



29/30

How to ApplyEligibility Criteria

Each academic year, the ICR invites applications or 15-20 our-year ull-time PhD studentships.In order to apply, students must meet the ollowing criteria:

Hold a rst or upper second class honours degree in a relevant subject (either expected or obtained)

rom a UK University OR hold an overseas qualication to the equivalent level

Have experience of laboratory or research work; one of your referees must be able to comment on

your research experience

Have a TOEFL score of 650 (paper-based), 280 (computer-based) or 114 (Internet-based) OR an IELTS

score o at least 7. Students without TOEFL or IETLS score should have either education experience in

English (min. 1 year) or work experience (min. 18 months)

Application GuidelinesAll applications must be made via the online orm.

A completed application consists o:

An online application form, where you have uploaded a summary of a research project and your

degree transcript i you are rom overseas.

Details of two references (one of whom must be able to comment on your research abilities)

Your referees will be contacted immediately. They will be emailed a link to a form which they

complete. You will receive an email when they have done this. I you do not receive this email, you

should contact your reerees: it is your responsibility to ensure that we receive your reerences

The deadline or applications is Wednesday 1st December 2010.I your application is successul you will be notied the week commencing Monday 20th December 2010

Interviews will be held rom Sunday 30th January Tuesday 1st February 2011.

LinksHow to Apply|The ICR Admission Policy| What to Expect at Interview

http://www.icr.ac.uk/education/science_students_opportunities/studentships/index.shtmlhttp://www.icr.ac.uk/education/science_students_opportunities/studentships/index.shtmlhttp://www.icr.ac.uk/education/science_students_opportunities/studentships/available_studentshi

Institute of Cancer

Documents

Transcript of Institute of Cancer